Erythropoietin is a hormone generated by the human renal system (kidney) that accelerates the pace of red blood cell formation in response to low oxygen levels in the tissues and aids in the process of erythropoiesis (red blood cell creation). Erythropoietin-stimulating drugs (EPO) are used to treat patients undergoing chemotherapy or HIV therapies. An expanding population with HIV, Cancer, and Renal illnesses is driving global demand for Erythropoietin (EPO) medications.
The global erythropoietin stimulating agent market research offers a detailed and comprehensive analysis of the global market, with a particular focus on future projections. The report is structured into various segments, each analyzing the factors and events that are likely to impact the market in the upcoming years.
Furthermore, the report includes Porter's Five Forces analysis that evaluates the competitive forces in the global market for global erythropoietin stimulating agent market, such as the bargaining power of customers and suppliers, the threat of new entrants, the threat of substitutes, and the level of competition among existing competitors. Additionally, the report offers insights into the market dynamics, such as market drivers, challenges, and opportunities.
Market Growth Drivers:
Rising Chronic Kidney Disease and Cancer Rates to Grow Market:
According to the CDC, adults 65 and older are more likely to have chronic kidney disease (38% prevalence), compared to those 18 to 44 years old (7%) and people 45 to 64 years old (13%). There is a developing need for erythropoietin-stimulating medications due to the rising incidence of this ailment and other renal diseases that directly affect blood cells.
Moreover, another reason contributing to the body's increasing need for blood cells is the rising prevalence of different diseases, including blood cancers. Over the course of the projected period, these variables are predicted to fuel market growth.
Market Restraints:
Side Effects Associated with ESAs to Restrict the Market Growth:
Patients who use erythropoietin-stimulating substances as medications have been documented to have several negative effects. Fever, swollen joints, elevated blood pressure, nausea, lightheadedness, and soreness at the injection site are a few examples. This is anticipated to limit market expansion throughout the anticipated timeframe.
Market Key Players:
The Global erythropoietin stimulating agents market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition.
- Amgen Inc.
- Biocon Limited
- Celltrion Inc.
- F. Hoffmann-La Roche Ltd
DataM Intelligence’s report on the erythropoietin stimulating agents market provides insights into the key drivers, challenges, top trends, and opportunities in the market. It also provides you with a geographical analysis and competitive landscape, which will paint a clear picture of the current market scenario.
To Gain deeper insights into the erythropoietin stimulating agents market and stay ahead of the competition, request a sample report from DataM Intelligence today.
To Know More Insights Download Sample
